Orchid Pharma Ltd
Orchid Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #74 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Q1 FY27 showed 15% YoY revenue growth and a 3 percentage point gross margin improvement.
From Orchid Pharma Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Q1 FY27 showed 15% YoY revenue growth and a 3 percentage point gross margin improvement.
- Management expects better Q-o-Q growth in H2 FY27, as regulated market demand typically picks up in the winter season.
- Volumes for key products like Exblifep in Europe exhibited significant sequential growth (300% in Q3 FY26, 170% in Q4 FY26, and 50% in Q1 FY27).
- The 7-ACA Jammu facility aims for commercial batch by March 2027 with ramp-up to 80-100% utilization by year-end.
- Long-term revenue from new products like Enmetazobactam has $1-2 billion lifetime sales potential.
- NP-NC segment sales were INR 21 crores in the recent quarter with ongoing incremental product additions.
2 more points from Orchid Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Orchid Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex is not expected to be very significant as major projects are nearing completion (Page 8).
- INR 750 crores capex for the 7-ACA project (Page 8).
- USD 20-25 million capex for the cefiderocol project (Page 8).
- Current financial year will see completion of cefiderocol and 7-ACA projects (Page 5).
- Strategic focus on backward integration into 7-ACA and cefiderocol access project to create diversified value (Page 5).
2 more points from Orchid Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Orchid Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Orchid Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Orchid Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹304 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Orchid Pharma's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Orchid Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Orchid Pharma Ltd Q1 FY27 results?
Q1 FY27 showed 15% YoY revenue growth and a 3 percentage point gross margin improvement.
What is Orchid Pharma Ltd share price analysis?
Orchid Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of 332.3 with a market cap of ₹6,001 Cr. Investors should review the full earnings analysis for detailed insights.
Is Orchid Pharma Ltd planning capital expenditure?
FY27 capex is not expected to be very significant as major projects are nearing completion (Page 8).
Keep Orchid Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.